Biosimulation Market to Surpass USD 4.2 Billion by 2026

The global biosimulation market was valued USD 1.3 billion in 2018, and is projected to exhibit a CAGR of 15.4 percent from 2018 – 2026. Modelling and simulation (M&S) or model-informed drug development are used at every phase/ stage of drug development process. Biosimulation software is being used in pharmaceutical drug development to mimic diseases. Virtual clinical trials of new developing pharmaceutical drugs can be conducted on computers running disease simulations. By using virtual patients instead of clinical research patients can significantly save time and money in pharmaceutical companies’ drug discovery research. Moreover, in order to avail these advantages of biosimulation, key players are increasingly using biosimulation software and services to speed up their research in rare disease management. For instance, in March 2012, Rhenovia Pharma initiated drug research programs in rare, orphan, and neglected diseases. Company aimed to expand their expertise in rare, orphan, and neglected disease such as Huntington’s disease (HD) and Duchenne muscular dystrophy (DMD) by improving diagnosis and treatment. Under this program, Rhenovia Pharma intends to build a new biosimulation platform targeted to model the complex structure between biological mechanisms in striatum, the brain region, which is most affected in HD.

Furthermore, the market is expected to exhibit high growth, owing to various strategic acquisitions by key players in the market in 2014-2017 period. For instance, in April 2014, Dassault Systèmes successfully completed the acquisition of Accelrys, Inc., a leading provider of scientific innovation lifecycle management software for chemistry, biology, and materials. Accelrys’ acquisition helped Dassault Systèmes to enhance its molecular chemistry capabilities, which is used in drug discovery and regulatory requirements of Dassault Systèmes’ formulation-based industry offerings such as life sciences, consumer packaged goods, high tech and energy, and advanced manufacturing industries. Moreover, in May 2014, after the completion of Accelrys’ acquisition, Dassault Systèmes launched its new brand BIOVIA, which is a combination of Dassault Systèmes’ BioIntelligence, and 3DEXPERIENCE technologies, and Accelrys’ life sciences and material sciences applications. Moreover, in July 2017, EQT AB announced plans to acquire Certara, L.P., a leading provider of model-informed drug development technology and services, for a deal value of USD  850 million. This new strategic partnership with EQT will enable Certara to strengthen their core offerings and help to uniquely positioned itself in the field of drug development. – Coherent Market Insights